The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine
Abstract
CONTEXT: In June 2006, the Food and Drug Administration licensed the quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccine (qHPV) in the United States for use in females aged 9 to 26 years; the Advisory Committee on Immunization Practices then recommended qHPV for routine vaccination of girls aged 11 to 12 years. OBJECTIVE: To summarize reports to the Vaccine Adverse Event Reporting System (VAERS) following receipt of qHPV. DESIGN, SETTING, AND PARTICIPANTS: Review and describe adverse events following immunization (AEFIs) reported to VAERS, a national, voluntary, passive surveillance system, from June 1, 2006, through December 31, 2008. Additional analyses were performed for some AEFIs in prelicensure trials, those of unusual severity, or those that had received public attention. Statistical data mining, including proportional reporting ratios (PRRs) and empirical Bayesian geometric mean methods, were used to detect disproportionality in reporting. MAIN OUTCOME MEASURES: Numbers of reported AEFIs, reporting rates (reports per 100,000 doses of distributed vaccine or per person-years at risk), and comparisons with expected background rates. RESULTS: VAERS received 12 424 reports of AEFIs following qHPV distribution, a rate of 53.9 reports per 100,000 doses distributed. A total of 772 reports (6.2% of all reports) described serious AEFIs, including 32 reports of death. The reporting rates per 100,000 qHPV doses distributed were 8.2 for syncope; 7.5 for local site reactions; 6.8 for dizziness; 5.0 for nausea; 4.1 for headache; 3.1 for hypersensitivity reactions; 2.6 for urticaria; 0.2 for venous thromboembolic events, autoimmune disorders, and Guillain-Barré syndrome; 0.1 for anaphylaxis and death; 0.04 for transverse myelitis and pancreatitis; and 0.009 for motor neuron disease. Disproportional reporting of syncope and venous thromboembolic events was noted with data mining methods. CONCLUSIONS: Most of the AEFI rates were not greater than the background rates compared with other vaccines, but there was disproportional reporting of syncope and venous thromboembolic events. The significance of these findings must be tempered with the limitations (possible underreporting) of a passive reporting system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061760 · Cited by 1,886
Markowitz, L. E., Dunne, E. F., Saraiya, M., Lawson, H. W., Chesson, H., & Unger, E. R. (2007) · PsycEXTRA Dataset · doi:10.1037/e601292007-001 · Cited by 1,882
Evans, S. J. W., Waller, P. C., & Davis, S. (2001) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.677 · Cited by 1,802
Le, M. (2007) · Medical Entomology and Zoology · Cited by 1,624
Dumouchel, W. (1999) · The American Statistician · doi:10.1080/00031305.1999.10474456 · Cited by 878
Chapter 1: Human Papillomavirus and Cervical Cancer--Burden and Assessment of Causality
Bosch, F. X., & de Sanjose, S. (2003) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a003479 · Cited by 826
SCHONBERGER, L. B., BREGMAN, D. J., SULLIVAN-BOLYAI, J. Z., KEENLYSIDE, R. A., ZIEGLER, D. W., RETAILLIAU, H. F., EDDINS, D. L., & BRYAN, J. A. (1979) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112795 · Cited by 785
Szarfman, A., Machado, S. G., & O??Neill, R. T. (2002) · Drug Safety · doi:10.2165/00002018-200225060-00001 · Cited by 700
Ault, K. A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60852-6 · Cited by 590
Block, S. L., Nolan, T., Sattler, C., Barr, E., Giacoletti, K. E. D., Marchant, C. D., Castellsagué, X., Rusche, S. A., Lukac, S., Bryan, J. T., et al. (2006) · Pediatrics · doi:10.1542/peds.2006-0461 · Cited by 484
Zhou, W., Pool, V., Iskander, J. K., English-Bullard, R., Ball, R., Wise, R. P., Haber, P., Pless, R., Mootrey, G. T., Ellenberg, S. S., et al. (2003) · PubMed · Cited by 400
The Vaccine Adverse Event Reporting System (VAERS)
(1994) · Vaccine · doi:10.1016/0264-410x(94)90044-2 · Cited by 392
Rüggeberg, J. U., Gold, M. S., Bayas, J.-M., Blum, M. D., Bonhoeffer, J., Friedlander, S., de Souza Brito, G., Heininger, U., Imoukhuede, B., Khamesipour, A., et al. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.02.064 · Cited by 383
Understanding vaccine safety information from the Vaccine Adverse Event Reporting System
VARRICCHIO, F., ISKANDER, J., DESTEFANO, F., BALL, R., PLESS, R., BRAUN, M. M., & CHEN, R. T. (2004) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200404000-00002 · Cited by 380
Chen, R. T., Glasser, J. W., Rhodes, P. H., Davis, R. L., Barlow, W. E., Thompson, R. S., Mullooly, J. P., Black, S. B., Shinefield, H. R., Vadheim, C. M., et al. (1997) · PEDIATRICS · doi:10.1542/peds.99.6.765 · Cited by 346
Novel Statistical Tools for Monitoring the Safety of Marketed Drugs
Almenoff, J. S., Pattishall, E. N., Gibbs, T. G., DuMouchel, W., Evans, S. J. W., & Yuen, N. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100258 · Cited by 266
Convulsive syncope in blood donors
Lin, J. T. ‐., Ziegler, D. K., Lai, C., & Bayer, W. (1982) · Annals of Neurology · doi:10.1002/ana.410110513 · Cited by 168
Active Surveillance of Vaccine Safety: A System to Detect Early Signs of Adverse Events
Davis, R. L., KOLCZAK, M. S., Lewis, E. M., Nordin, J. D., Goodman, M. J., Shay, D. K., Platt, R. G., BLACK, S. B., Shinefield, H. R., & Chen, R. T. (2005) · Epidemiology · doi:10.1097/01.ede.0000155506.05636.a4 · Cited by 148
Syncope after vaccination - United States, January 2005-July 2007
(2008) · PsycEXTRA Dataset · doi:10.1037/e458092008-002 · Cited by 128
Braun, M. M. (1997) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.1997.02170400041007 · Cited by 100
Guillain-Barr� syndrome: Its epidemiology and associations with influenza vaccination
Schonberger, L. B., Hurwitz, E. S., Katona, P. G., Holman, R. C., & Bregman, D. J. (1981) · Annals of Neurology · doi:10.1002/ana.410090707 · Cited by 98
Gomes, M. P. V., & Deitcher, S. R. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.18.1965 · Cited by 44
Fatal Syncope-Related Fall After Immunization
Woo, E. J., Ball, R., & Braun, M. M. (2005) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.159.11.1083 · Cited by 31
Cited by
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
Joura, E. A., Giuliano, A. R., Iversen, O.-E., Bouchard, C., Mao, C., Mehlsen, J., Moreira, E. D., Ngan, Y., Petersen, L. K., Lazcano-Ponce, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405044 · Cited by 1,433
Andreoli, L., Bertsias, G. K., Agmon-Levin, N., Brown, S., Cervera, R., Costedoat-Chalumeau, N., Doria, A., Fischer-Betz, R., Forger, F., Moraes-Fontes, M. F., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209770 · Cited by 945
A review of clinical trials of human papillomavirus prophylactic vaccines
Schiller, J. T., Castellsagué, X., & Garland, S. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.108 · Cited by 747
van Assen, S., Agmon-Levin, N., Elkayam, O., Cervera, R., Doran, M. F., Dougados, M., Emery, P., Geborek, P., Ioannidis, J. P. A., Jayne, D. R. W., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.137216 · Cited by 630
Metadata
- Authors
- Slade, B. A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2009-08-19
- Volume
- 302
- Issue
- 7
- Pages
- 750
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2153475181
- Cited by
- 470
- References
- 24
- FWCI
- 31.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.